Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes
Authors:
- 1 August 1996
- journal article
- review article
- Published by Elsevier in Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
- Vol. 355 (1-2) , 91-101
Abstract
No abstract availableKeywords
Funding Information
- Cancer Society of New Zealand
This publication has 52 references indexed in Scilit:
- Experimental solid tumour activity ofN-[2-(dimethylamino)ethyl]-acridine-4-carboxamideCancer Chemotherapy and Pharmacology, 1995
- Genotoxicity of 17 gyrase- and four mammalian topoisomerase II-poisons in prokaryotic and eukaryotic test systemsMutagenesis, 1995
- Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cellsBiochemical Pharmacology, 1994
- potent clastogenicity of the human carcinogen etoposide to the mouse bone marrow and mouse lymphoma L5178Y cells: Comparison to salmonella responsesEnvironmental and Molecular Mutagenesis, 1994
- Poly(ADP-ribosyl)ation, DNA strand breaks, chromatin and cancerToxicology Letters, 1993
- Genotoxicity of inhibitors of DNA topoisomerases I (camptothecin) and II (m-AMSA) in vivo and in vitroMutagenesis, 1990
- A Special Role for Amsacrine in the Treatment of Acute LeukemiaCancer Investigation, 1989
- Inhibition of type II topoisomerase by fostriecinBiochemical Pharmacology, 1988
- Inverse correlation between bacterial frameshift mutagenicity and yeast mitochondrial effects of antitumour anilinoacridinesChemico-Biological Interactions, 1985
- Mutagenic and cytotoxic activity of doxorubicin and daunorubicin derivatives on prokaryotic and eukaryotic cellsBritish Journal of Cancer, 1984